ViiV Healthcare press release
ViiV Healthcare announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study. In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular long-acting cabotegravir, maintained viral suppression in 94% of participants receiving lotivibart intravenously and 82% subcutaneously, compared with 88% in the standard of care group.
These favourable data reinforce lotivibart’s ultra long-acting potential (dosing every four months or longer).
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.